Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Joseph Haas

Senior Writer

Washington, DC

Joe has covered a wide range of biopharmaceutical stories since 2007 and contributes to Scrip, In Vivo, Pink Sheet and related Citeline publications. His specialties include business development, commercial strategies and liver and infectious diseases.

Latest From Joseph Haas

Sarepta Obtains Broader DMD Label For Elevidys

The gene therapy is now approved for all ambulatory boys with Duchenne muscular dystrophy ages 4 and older. The revised label also includes accelerated approval for non-ambulatory patients.

Approvals Gene Therapy

Gilead’s Twice-Annual Sunlenca Posts Zero Infection Rate In PrEP Trial

Lenacapavir is halfway to the pivotal data needed to file for twice-annual administration in PrEP, after demonstrating superiority against both background incidence of HIV infections and Truvada.

Clinical Trials Business Strategies

Intra-Cellular Poised To Add MDD To Caplyta’s Label

Caplyta succeeded in a second Phase III study as adjunctive therapy for major depression, putting the schizophrenia/bipolar disorder drug on track for sNDA filing later in 2024.

Clinical Trials Business Strategies

Marinus Considers Its Options After Mixed Phase III Data

Ganaxolone met one of two endpoints in its Phase III refractory status epilepticus trial, but next steps are uncertain. Analysts say the firm should focus on a more promising trial, but Marinus thinks conditional approval is possible.

Clinical Trials Drug Approval Standards

Asia Deal Watch: Chugai Extends Relationship With Helsinn

Plus deals involving Kissei/JWP, Shionogi/Cilcare, Takeda/Torrent, Genome & Co./Debiopharm, Kaken/J&J, CStone/Ewopharma, MediLink/BioNTech and more.

Deal Watch Business Strategies

Bristol Gets Tumor-Agnostic Second Approval For Augtyro

Already approved for lung cancer, BMS’s ROS1/NTKK inhibitor gets US FDA accelerated approval for solid tumors that are NTRK-fusion positive.

Approvals Business Strategies
See All
UsernamePublicRestriction

Register